Integra LifeSciences (NASDAQ:IART) Price Target Raised to $11.00 at Citigroup

Integra LifeSciences (NASDAQ:IART) had its price target raised by analysts at Citigroup from $9.00 to $11.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “sell” rating on the life sciences company’s stock. Citigroup’s target price indicates a potential downside of 21.33% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Truist Financial dropped their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Finally, Wells Fargo & Company increased their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Integra LifeSciences has an average rating of “Reduce” and an average target price of $15.20.

Integra LifeSciences Price Performance

NASDAQ IART traded up $0.76 during trading hours on Wednesday, hitting $13.98. 1,378,274 shares of the company’s stock traded hands, compared to its average volume of 822,817. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $16.49. The company has a market capitalization of $1.09 billion, a PE ratio of -2.09 and a beta of 1.08. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The firm’s 50-day moving average is $10.11 and its 200-day moving average is $11.73.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the prior year, the company earned $0.41 EPS. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities analysts forecast that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP boosted its position in shares of Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares during the period. Invesco Ltd. boosted its position in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after purchasing an additional 31,931 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after purchasing an additional 267,134 shares during the period. State Street Corp boosted its position in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after purchasing an additional 21,717 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its position in shares of Integra LifeSciences by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after purchasing an additional 135,198 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

More Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 beat — Integra reported EPS of $0.54 vs. consensus $0.41 and revenue $391.9M vs. ~$381.8M, showing sequential strength and a year‑over‑year revenue increase; this explains much of the bullish reaction. MarketBeat Q1 Results
• Positive Sentiment: FY 2026 raised/firm — management set FY 2026 EPS guidance at $2.40–$2.50, above consensus ~2.35, which supports a stronger full‑year outlook despite mixed near‑term guidance. GlobeNewswire FY Guidance
• Positive Sentiment: Analyst action — Wells Fargo raised its price target to $15 (from $12) and kept an “equal weight” rating, providing incremental support for the rally. Benzinga Note on Wells Fargo
• Neutral Sentiment: Leadership change — the company announced Stuart Essig as President & CEO and Michael McBreen as Chief Commercial Officer; leadership transitions can be positive long term but add short‑term execution uncertainty. GlobeNewswire Leadership Release
• Neutral Sentiment: Earnings materials available — full Q1 call transcript, slide deck and press release are posted for investors to review execution detail and segment trends. Seeking Alpha Transcript
• Negative Sentiment: Near‑term guide softening — Q2 EPS was guided to $0.44–$0.52 and revenue to ~$410M–$425M, below the Q2 consensus (~$0.53 EPS, ~$425M revenue), which could pressure the stock if investors focus on the quarterly miss rather than the raised full‑year view. Zacks Q1 & Guidance Analysis

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.